Benzodioxolylbutanamine (BDB) is a synthetic chemical compound classified within the substituted phenethylamine and amphetamine families. It is a structural analogue of MDA and MDMA, characterized by its entactogenic and serotonergic properties as observed in pharmacological and animal studies. BDB has gained attention in chemical research for its unique behavioral and neurochemical profile, offering an alternative model for studying empathogenic compounds and monoaminergic neurotransmission.

• Chemical Classification
  BDB is a substituted phenethylamine and amphetamine derivative featuring a methylenedioxy ring. This structure is closely related to MDA, sharing the 1,3-benzodioxole group with an altered aliphatic side chain.

• Molecular Formula and Structure
  Its molecular formula is C11H15NO2. The compound contains a central phenethylamine skeleton with a 1,3-benzodioxole ring, making it structurally and functionally similar to several well-known entactogens.

• Research Significance
  BDB is primarily studied for its potential to induce emotional enhancement, serotonin release, and pro-social behaviors in controlled experimental models.

• Pharmacological Profile
  While not as potent as MDMA, BDB is reported to show selective serotonin release and weak dopaminergic action, making it a valuable compound in receptor binding and monoamine transporter studies.

• Entactogenic Properties
  In animal research, BDB has displayed empathogenic-like responses—emotional warmth, reduced anxiety, and increased social interaction—without intense stimulation.

• Unscheduled Legal Status
  BDB remains unscheduled in many regions but may fall under analogue or psychoactive substance regulations depending on local laws.

• Use in Neurotransmitter Transporter Studies
  Its effects on serotonin (SERT) and norepinephrine (NET) transporters are of specific interest to neurochemical researchers evaluating entactogen structure-activity relationships.

Benzodioxolylbutanamine (BDB) is not classified as a controlled substance in many jurisdictions, which allows its purchase for legitimate scientific research. However, legality can vary based on local analog laws and specific national regulations, particularly those targeting structural similarity to scheduled substances.

• Unscheduled Status Globally
  BDB does not appear on the controlled substance lists of most countries, including the United States, meaning it is technically legal to possess for research purposes.

• Subject to Analogue Laws
  In countries like the U.S., compounds structurally similar to scheduled substances may be subject to prosecution under analogue laws if intended for human consumption.

• EU and UK Considerations
  Some European countries and the United Kingdom have broader psychoactive substance bans that could encompass BDB depending on context and interpretation.

• RC Plug Compliance Policy
  We ship BDB only to destinations where it is clearly legal for research purposes and prohibit its use for recreational or unauthorized applications.

• Buyer Responsibility
  Researchers are expected to verify local laws prior to purchasing. RC Plug does not accept liability for improper importation or usage.

• No Prescription Needed
  Because BDB is not recognized as a pharmaceutical compound, it does not require a prescription and is sold strictly under research-only terms.

• Legally Packaged for Customs Clearance
  All BDB shipments are labeled in accordance with legal chemical handling practices to ensure smooth customs processing when applicable.

The chemical structure of BDB plays a central role in its function as a serotonergic research chemical. Its resemblance to compounds like MDA and MDMA makes it a valuable analog for exploring subtle changes in receptor interaction and entactogenic behavior. The structural design of BDB includes essential pharmacophores that influence its neuroactivity.

• Core Structure
  BDB features a phenethylamine backbone with a methylenedioxy ring at the 3,4-position, forming a benzodioxole—a key functional group in serotonin-affecting agents.

• Aliphatic Chain Modification
  Unlike MDMA, BDB has a butan-2-amine side chain rather than a methyl substitution on the amine, giving it a slightly different interaction profile at monoamine transporters.

• IUPAC Naming
  Its full IUPAC name is 1-(1,3-benzodioxol-5-yl)butan-2-amine, which defines the molecular positioning of functional groups and assists with proper chemical cataloging.

• Molecular Weight and Formula
  With a molecular weight of 193.24 g/mol and a molecular formula of C11H15NO2, BDB is suitable for quantitative studies involving molecular diffusion and binding kinetics.

• Functional Group Activity
  The 1,3-benzodioxole moiety contributes to serotonin transporter activity, while the amine group plays a role in central nervous system penetration in theoretical pharmacology.

• 3D Configuration
  BDB exists as a chiral compound, though most available research-grade material is racemic unless otherwise specified, which may influence binding affinity and enantiomer-specific outcomes.

• Comparative Relevance
  The structural similarity to MDA and MBDB allows BDB to serve as a useful scaffold for developing new serotonergic probes or conducting structure-activity relationship (SAR) experiments.

BDB has a range of applications across neuropharmacology, behavioral science, and chemical modeling. Its ability to modulate serotonin levels and its relatively mild psychopharmacological profile make it particularly relevant for studies that require entactogenic but not highly stimulatory effects.

• Monoamine Transporter Studies
  BDB is often used to study serotonin transporter (SERT) interactions, helping researchers understand how structural analogues affect reuptake inhibition or release.

• Receptor Binding Assays
  The compound is a candidate for in vitro testing of serotonin and norepinephrine receptor activity, particularly at 5-HT2A, 5-HT1A, and related binding sites.

• Behavioral Pharmacology
  BDB is administered to lab animals (where permitted) to evaluate social bonding, anxiety modulation, and empathogenic-like effects without the stimulation of MDMA.

• Structure-Activity Relationship (SAR) Research
  As part of the MDxx chemical family, BDB contributes valuable insights into how slight structural changes influence psychoactivity and duration.

• Neurotoxicity Profiling
  Unlike MDMA, BDB appears to present lower neurotoxicity risks in in vitro studies, making it a compound of interest in harm-reduction and toxicity comparisons.

• Comparative Pharmacodynamics
  It is used alongside analogs such as MDA, MBDB, and MDMA to contrast potency, duration, and neurotransmitter selectivity in academic publications.

• Chemical Modeling
  BDB’s stable structure allows it to be used in computational modeling to predict receptor interactions and molecular docking outcomes in CNS targets.

Proper storage of Benzodioxolylbutanamine is essential to maintain its purity, stability, and usability in long-term research applications. Because it is a sensitive compound, BDB requires controlled environmental conditions to prevent degradation from light, temperature shifts, and moisture exposure.

• Ideal Temperature
  Store BDB at or below -20°C in a freezer unit dedicated to chemical substances. Consistent cold storage slows down any molecular breakdown or oxidative changes.

• Moisture Avoidance
  Always keep the compound in a moisture-free environment. Desiccants such as silica gel can be used within storage containers to absorb humidity.

• Light Protection
  BDB should be shielded from direct light, especially UV, which may alter its chemical structure. Use amber vials or wrap containers in foil if necessary.

• Air-Tight Sealing
  Exposure to oxygen can lead to slow oxidation, affecting both potency and safety. Use air-tight, vacuum-sealed containers to prevent air ingress.

• Proper Labeling
  All containers should be clearly labeled with compound name, concentration, date of synthesis or packaging, and hazard classification for lab safety compliance.

• Batch Tracking
  Maintain a log of storage conditions, lot numbers, and expiration estimates to ensure reliable traceability and research integrity.

• Avoid Frequent Opening
  If using the compound repeatedly, portion out smaller quantities for active use to minimize the exposure of the main bulk to atmospheric conditions.

BDB and MBDB are structurally similar compounds, both belonging to the entactogen family and derived from the phenethylamine class. The main distinction lies in their amine group substitution—BDB is a primary amine, while MBDB is an N-methylated version. These structural variations affect their pharmacokinetics, subjective effects in animal studies, and transporter binding efficiency. In research contexts, the choice between BDB and MBDB often depends on the desired balance between potency, duration, and stimulation.

• Structural Distinction
  BDB has a butanamine side chain with a free primary amine, while MBDB contains an additional methyl group on the nitrogen atom, forming a secondary amine. This small alteration leads to significant differences in receptor activity.

• Potency and Onset
  BDB generally exhibits a slightly higher potency and faster onset in comparison studies, while MBDB is milder and slower-acting, with less stimulation and emotional intensity.

• Duration of Action
  MBDB is typically reported to have a longer duration with a smoother, more gradual curve in observed effects, whereas BDB presents a more defined peak with a quicker resolution phase.

• Stimulation vs. Sedation Balance
  BDB tends to be slightly more stimulating and emotionally engaging, whereas MBDB is commonly described as more relaxing and less intrusive in animal behavioral assays.

• Neurotransmitter Release Profiles
  MBDB appears to favor serotonin release over dopamine or norepinephrine, making it less stimulating and less reinforcing in neurochemical evaluations. BDB, while still serotonergic, shows a slightly broader transporter interaction.

• Research Application Preference
  For studies focused on empathetic or pro-social behaviors without excessive stimulation, MBDB may be preferred. In contrast, BDB may be selected when evaluating sharper entactogenic responses or mixed transmitter modulation.

• Toxicological Differences
  Neither compound shows high neurotoxicity in vitro, but MBDB is often considered slightly safer due to its reduced dopaminergic activity, potentially lowering oxidative stress markers.

Accurate measurement of BDB is critical for maintaining consistency across research protocols. Because of its potent activity and need for precise dosing, researchers employ sensitive instruments and standardized protocols to ensure reproducibility. All measurements should be performed in a controlled lab setting with calibrated equipment and protective gear.

• Use of Precision Scales
  BDB must be weighed using high-resolution analytical balances (0.1 mg or better) to avoid dosage discrepancies. These scales should be calibrated before each session using certified weights.

• Microdosing Techniques
  In microgram or low milligram experiments, a volumetric dosing method is often employed. This involves dissolving a known mass of BDB in a precise volume of solvent to create an accurate concentration for titration.

• Protective Lab Environment
  Researchers must use gloves, lab coats, and containment hoods when handling BDB, especially when preparing solutions or working with volatile solvents.

• Documentation Practices
  Lab notebooks should include detailed logs of weight, solvent used, concentration prepared, batch number, and time of measurement for regulatory and quality control compliance.

• Dissolution in Analytical Solvents
  If used in chromatographic or spectroscopic studies, BDB can be dissolved in ethanol, methanol, or DMSO. The chosen solvent must be compatible with the research equipment and study objectives.

• Batch Aliquoting for Consistency
  Researchers often divide BDB into multiple small aliquots to prevent repeated exposure of the bulk sample to air or moisture, preserving compound integrity.

• Standard Operating Procedures (SOPs)
  Laboratories working with BDB are encouraged to create SOPs that standardize measurement, storage, and labeling processes to ensure accuracy and reproducibility.

Benzodioxolylbutanamine (BDB) typically appears as a white or off-white crystalline powder. Its physical properties are consistent with other compounds in the substituted phenethylamine family. Understanding its appearance is important for visual identification, although purity and identity must be confirmed through analytical testing.

• Color
  BDB is usually a fine, white to off-white powder. Any deviation in color may indicate impurities or degradation, especially if yellowing or clumping is observed.

• Texture
  The compound can range from a soft, fluffy powder to a slightly crystalline or granular consistency, depending on synthesis conditions and storage.

• Odor
  Pure BDB is generally odorless. However, a faint chemical smell may be present due to trace solvent residues from synthesis if not fully evaporated.

• Moisture Sensitivity
  When exposed to air or humidity, BDB may clump or change texture slightly. This does not necessarily imply contamination but indicates improper storage.

• Packaging Format
  At RC Plug, BDB is sealed in clear vacuum-sealed bags or amber vials, each labeled with batch data, to ensure clarity and traceability upon delivery.

• Particle Size
  While not usually micronized, BDB’s particle size is sufficient for standard solution preparation, chromatography, or weighing protocols.

• Visual Quality Control
  Before analytical testing, researchers often perform a visual inspection to identify any particulate contamination or moisture before use.

The shelf life and stability of BDB depend on storage conditions, particularly exposure to moisture, air, and light. When stored under optimal laboratory conditions, BDB retains its integrity and research-grade quality for extended periods, making it viable for long-term use in planned study phases.

• General Shelf Life
  When stored properly, BDB remains stable for at least 24 months. Beyond this point, a reevaluation through purity testing is recommended before further use.

• Temperature Recommendations
  Keeping BDB at sub-zero temperatures (preferably -20°C) significantly extends its usable life by slowing molecular degradation processes.

• Protection from Light
  Light, especially UV, can initiate photochemical reactions. BDB should be stored in amber vials or foil-wrapped containers to block light exposure.

• Air-Tight Sealing
  Oxygen can promote slow oxidation. Once opened, the compound should be resealed promptly or aliquoted into smaller containers to limit air contact.

• Humidity Control
  Moisture is one of the main threats to stability. Desiccants inside the storage container or refrigerator compartment can help mitigate humidity risks.

• Recrystallization Warning Signs
  If visible discoloration, liquefaction, or unexpected clumping occurs, it may indicate degradation. Such batches should be retested or discarded.

• Retesting Practices
  For long-term stored BDB, reanalysis via HPLC, GC-MS, or NMR is advised every 6–12 months to confirm ongoing suitability for research.

No. BDB is not approved for human consumption and must be handled strictly within the framework of authorized chemical research. Despite its structural relation to known entactogens, there is insufficient toxicological, pharmacokinetic, and clinical data to consider BDB safe for ingestion or recreational use.

• Research-Only Designation
  BDB sold by RC Plug is intended solely for in vitro, analytical, or animal research use (where legally permitted), and is not manufactured or labeled for human use.

• Lack of Human Safety Data
  There are no peer-reviewed toxicology studies or clinical trials that validate safe dosing, metabolism, or elimination pathways of BDB in humans.

• Potential Health Risks
  As with many novel phenethylamines, unregulated use could pose serious risks including serotonergic toxicity, cardiovascular strain, or long-term neurological impact.

• Legal Implications
  Using or distributing BDB for non-research purposes may violate local analogue or psychoactive substance laws, leading to criminal charges.

• Occupational Safety Measures
  Laboratory personnel must use gloves, protective eyewear, and work within fume hoods when handling the compound to avoid skin contact or inhalation.

• No Medical Applications
  BDB is not approved by any national health authority, including the FDA or EMA, and has no therapeutic indications or prescription use.

• RC Plug Compliance Policy
  We maintain a strict policy against misuse and clearly label all products as not for human or animal consumption, consistent with international chemical supply regulations.

Yes, Benzodioxolylbutanamine (BDB) is often used in receptor binding assays to evaluate its interaction with central nervous system receptors, particularly those involved in the modulation of mood and behavior. These assays help quantify BDB’s affinity and efficacy across different binding sites, most notably within the serotonin receptor family, making it highly relevant for neurochemical research models.

• 5-HT2A Receptor Interaction
  BDB is structurally compatible with serotonin 2A receptor assays, commonly used to explore compounds with potential entactogenic or hallucinogenic properties in vitro.

• Serotonin Transporter (SERT) Affinity
  Studies frequently utilize BDB in assays targeting the SERT protein to evaluate its serotonin reuptake inhibition profile and to compare activity to MDMA or MDA analogs.

• Low Dopaminergic Affinity
  BDB has shown lower affinity for dopamine transporters compared to stimulants like amphetamine, making it a safer candidate for selective serotonergic research.

• In Vitro Functional Assays
  BDB can be applied to cell-based assays involving radioligand binding or fluorescent reporter systems to determine EC50, IC50, or Ki values for target receptors.

• SAR Comparative Studies
  Researchers employ BDB to contribute to structure-activity relationship (SAR) evaluations across a series of MDxx analogs to map chemical moieties and receptor response.

• Non-Hallucinogenic Entactogen Modeling
  Receptor binding results suggest that BDB is more aligned with entactogens than psychedelics, with reduced affinity for hallucinogen-associated receptors like 5-HT2C.

• Testing with Recombinant Cell Lines
  Commercially available cell lines expressing human receptor subtypes (e.g., HEK293 or CHO cells) are commonly used to assess BDB’s selective binding properties.

BDB has demonstrated entactogenic-like properties in animal research settings, particularly in controlled rodent studies. These effects include increased social interaction, reduced anxiety behaviors, and moderate locomotor stimulation—common markers of entactogen activity. While behavioral responses can vary by species and dose, BDB is frequently studied as a model compound for understanding emotional regulation mechanisms.

• Pro-Social Behavior Enhancements
  Rodents administered BDB often show increased social grooming, interaction, and cooperative exploration, mimicking the pro-social effects observed with MDMA.

• Anxiolytic-Like Properties
  In elevated plus maze and open field tests, BDB has been reported to reduce avoidance behavior and increase exploration, suggesting a potential anxiolytic action.

• Reduced Aggression in Models
  Unlike stimulants that can provoke aggression in rodents, BDB tends to reduce territorial and defensive behaviors in male subjects.

• Mild Stimulant Action
  BDB induces moderate locomotor activity, which is significantly lower than that of MDA or amphetamine, indicating a less stimulating pharmacological profile.

• Lack of Stereotypy
  At research-relevant doses, BDB does not produce stereotypic behaviors (e.g., repetitive sniffing or head weaving), which are common in dopaminergic overstimulation.

• Comparative Reference Use
  BDB is often used alongside MDMA and MBDB in entactogenic comparison studies to distinguish subtle variations in social and affective response.

• Potential for Emotional Processing Models
  Its observed behaviors make BDB a useful candidate for studying emotional processing, reward circuitry, and oxytocin-mediated pathways in preclinical research.

Mixing BDB with other research chemicals should be approached with scientific caution and only conducted under tightly controlled experimental protocols. Although some comparative and combination studies may provide insights into synergistic or antagonistic effects, combining compounds without comprehensive analysis risks confounding data and compromising safety standards in laboratory environments.

• Recommended for Comparative, Not Combined, Study
  It is more advisable to study BDB side-by-side with other compounds rather than concurrently unless the research specifically investigates interactions.

• Unpredictable Pharmacodynamics
  Combining compounds that act on similar or overlapping neurotransmitter systems, like MDMA and BDB, can lead to complex or unpredictable outcomes in vitro and in vivo.

• Confounding Variables in Data
  Co-administration may obscure individual pharmacokinetic or pharmacodynamic profiles, complicating efforts to isolate specific receptor or behavioral responses.

• Heightened Serotonergic Load
  When combined with other serotonergic agents, BDB may contribute to excess serotonin release or reuptake inhibition, risking serotonin syndrome-like effects in animal models.

• Toxicity Concerns
  Toxicological responses, including hepatotoxicity or neurotoxicity, could increase with combined chemical stress, particularly in long-term or high-dose studies.

• Ethical and Regulatory Limits
  Institutional guidelines or chemical licensing terms may prohibit the mixing of certain unscheduled compounds due to liability or biosafety classification.

• Protocol Design Must Be Documented
  If combining BDB with other compounds is scientifically necessary, it must be clearly justified in the study protocol, with dose calculations, solvent compatibility, and batch traceability documented meticulously.

Understanding BDB’s solubility profile is essential for researchers preparing solutions for chromatography, spectroscopy, or biochemical assays. BDB is moderately soluble in a range of organic solvents but exhibits limited solubility in water, which should be considered when selecting dissolution media or storage vehicles.

• Solubility in Ethanol
  BDB dissolves well in ethanol, making it a suitable choice for preparing intermediate stock solutions for chemical or spectrophotometric testing.

• Moderate DMSO Solubility
  Dimethyl sulfoxide (DMSO) is another effective solvent, commonly used in biological research to introduce BDB into aqueous systems or cell cultures with proper dilution.

• Low Water Solubility
  BDB has poor solubility in distilled water or saline, limiting its use in purely aqueous solutions unless modified with co-solvents or surfactants.

• Compatibility with Acetone and Methanol
  BDB is also soluble in acetone and methanol, which are often used in chemical synthesis or purification steps like recrystallization or thin-layer chromatography.

• Formulation for Injectables (Animal Models)
  In animal research, BDB is typically dissolved in a small amount of DMSO or ethanol and diluted with saline or buffered solutions for subcutaneous or intraperitoneal administration.

• Need for Filtration
  After dissolution, solutions should be filtered using 0.2–0.45 µm syringe filters to remove particulates or undissolved residues, ensuring sterile preparation.

• Temperature-Dependent Solubility
  Solubility increases with temperature, so mild warming (not exceeding 40°C) can aid in dissolving stubborn crystals during stock preparation.

BDB and MDMA share significant structural similarities, yet their pharmacological profiles diverge in terms of potency, duration, neurochemical selectivity, and observed subjective effects in research models. While both are considered entactogens, MDMA is generally more potent, faster-acting, and more stimulating, whereas BDB offers a subtler, longer-lasting response.

• Structural Similarity
  Both compounds feature the methylenedioxyphenethylamine core, with BDB differing primarily in its butylamine chain and absence of N-methylation.

• Potency and Effective Dose
  MDMA is notably more potent by weight in behavioral and receptor binding assays. BDB typically requires a higher dose to produce similar serotonergic outcomes.

• Onset and Duration
  MDMA has a rapid onset and shorter peak duration (~4–6 hours in animal models), while BDB’s effects onset more gradually and may last up to 8 hours depending on dosage.

• Serotonin vs Dopamine Activity
  MDMA acts on serotonin, dopamine, and norepinephrine transporters, contributing to its strong stimulant and reinforcing properties. BDB is more selective for serotonin and norepinephrine, showing lower dopaminergic engagement.

• Behavioral Profile
  MDMA increases locomotion, tactile stimulation, and sociability more prominently. BDB is gentler, with emotional openness and relaxation without pronounced stimulation.

• Neurotoxicity Comparison
  MDMA has a well-documented neurotoxic risk in serotonergic neurons, especially at high doses or repeated exposure. BDB appears less neurotoxic but lacks comprehensive long-term data.

• Application in Research
  MDMA is widely used in studies of PTSD, prosocial behavior, and abuse liability. BDB, with its smoother profile, is suitable for examining entactogenic mechanisms without the interference of high stimulation.

Yes, every batch of Benzodioxolylbutanamine (BDB) distributed by RC Plug is tested before shipment to confirm its chemical identity, structural integrity, and purity. We understand the importance of consistency and verification in scientific research, which is why we ensure rigorous quality control standards are upheld at every stage of the supply chain.

• GC-MS Testing
  Gas chromatography-mass spectrometry (GC-MS) is used to verify the molecular identity of BDB and detect any impurities or byproducts from synthesis.

• NMR Spectroscopy
  Nuclear magnetic resonance (NMR) spectroscopy is performed to confirm structural configuration and ensure the integrity of the compound’s functional groups.

• Purity Assessment
  Each batch is assessed for purity, with RC Plug guaranteeing ≥98% minimum purity for all BDB products. Impurity levels are documented in the accompanying Certificate of Analysis (COA).

• Visual and Physical Inspections
  Trained chemists perform visual inspections to confirm expected appearance, color, and consistency. Any deviation results in immediate disqualification of the batch.

• Moisture and Residue Solvent Analysis
  Testing includes analysis for residual solvents, moisture content, and volatile organic compounds to ensure product stability and research safety.

• Batch Traceability
  Every unit of BDB is labeled with a unique batch number and packaging date, which links it to its full analytical record.

• On-Request Documentation
  Researchers can request a detailed COA with their order, providing transparency and confidence in the product’s composition.